Cholesterol-lowering drug Repatha (evolocumab) has been approved by Japan’s Ministry of Health, Labour and Welfare.
Repatha was developed in Japan by Amgen Astellas BioPharma K.K. (AABP), a joint venture between Amgen (Nasdaq: AMGN) and Tokyo-based Astellas Pharma (TYO: 4503) .
It is the first proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor to be approved in Japan, where it is indicated for the treatment of patients with familial hypercholesterolemia (FH) or hypercholesterolemia who have high risk of cardiovascular illness and do not adequately respond to statins.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze